Remdesivir was given an EUA at the interim report of its Phase 3 study. That's my best guess for Brilacin.
It could be sooner if the Phase 2 shows outstanding results, acing all the primary and secondary outcomes with absolute safety.
The other factor is the status of the pandemic. If the Delta virus outbreak continues to accelerate or if vaccine resistant or more deadly variants appear, Brilacidin could be pushed up to the drug of choice.